Vertex Pharmaceuticals Incorporated Share Price Today: Live Updates & Key Insights
Vertex Pharmaceuticals Incorporated share price today is $478.15, up -2.89%. The stock opened at $488 against the previous close of $492.38, with an intraday high of $489.26 and low of $476.57.
Vertex Pharmaceuticals Incorporated Share Price Chart
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated Share Price Performance
Vertex Pharmaceuticals Incorporated Institutional Holdings
Vertex Pharmaceuticals Incorporated Market Status
Vertex Pharmaceuticals Incorporated Fundamentals
Market Cap 125064.52 M
PB Ratio 6.7011
PE Ratio 32.1607
Enterprise Value 120503.75 M
Total Assets 26142.80 M
Volume 1607828
Vertex Pharmaceuticals Incorporated Company Financials
About Vertex Pharmaceuticals Incorporated & investment objective
Company Information Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Organisation Biotechnology
Employees 6400
Industry Biotechnology
CEO Dr. Reshma Kewalramani FASN, M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
